Cargando…

A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC

BACKGROUND: It is still unclear how to combine biomarkers to identify patients who will truly benefit from anti-PD-1 agents in NSCLC. This study investigates exosomal mRNA expression of PD-L1 and IFN-γ, PD-L1 polymorphisms, tumor mutational load (TML) in circulating cell-free DNA (cfDNA) and radiomi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Re, Marzia, Cucchiara, Federico, Rofi, Eleonora, Fontanelli, Lorenzo, Petrini, Iacopo, Gri, Nicole, Pasquini, Giulia, Rizzo, Mimma, Gabelloni, Michela, Belluomini, Lorenzo, Crucitta, Stefania, Ciampi, Raffaele, Frassoldati, Antonio, Neri, Emanuele, Porta, Camillo, Danesi, Romano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139911/ https://www.ncbi.nlm.nih.gov/pubmed/33315149 http://dx.doi.org/10.1007/s00262-020-02810-6

Ejemplares similares

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment
por: Del Re, Marzia, et al.
Publicado: (2017)

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
por: Del Re, Marzia, et al.
Publicado: (2019)

Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer
por: Cucchiara, Federico, et al.
Publicado: (2020)

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
por: Del Re, Marzia, et al.
Publicado: (2019)

Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer
por: Del Re, Marzia, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021)

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
por: Del Re, Marzia, et al.
Publicado: (2018)

Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
por: Arrigoni, Elena, et al.
Publicado: (2018)

The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs
por: Del Re, Marzia, et al.
Publicado: (2022)

Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
por: Rizzo, Mimma, et al.
Publicado: (2021)

Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis
por: Rizzo, Mimma, et al.
Publicado: (2022)

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
por: Del Re, Marzia, et al.
Publicado: (2017)

Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients
por: Martignano, Filippo, et al.
Publicado: (2021)

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
por: Petrini, Iacopo, et al.
Publicado: (2022)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

Imaging biomarkers in upper gastrointestinal cancers
por: Gabelloni, Michela, et al.
Publicado: (2019)

Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors
por: Pezzicoli, Gaetano, et al.
Publicado: (2021)

A Glimpse in the Future of Malignant Mesothelioma Treatment
por: Pezzicoli, Gaetano, et al.
Publicado: (2021)

IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Rizzo, Mimma, et al.
Publicado: (2022)

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
por: Del Re, Marzia, et al.
Publicado: (2022)

Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma
por: Barkan, Ella, et al.
Publicado: (2023)

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
por: Del Re, Marzia, et al.
Publicado: (2016)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

Radiomics and liquid biopsy in oncology: the holons of systems medicine
por: Neri, Emanuele, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
por: Bronte, Giuseppe, et al.
Publicado: (2023)

Are Semiquantitative Methods Superior to Deauville Scoring in the Monitoring Therapy Response for Pediatric Hodgkin Lymphoma?
por: Ibrahim, Firuz, et al.
Publicado: (2023)

Understanding EGFR heterogeneity in lung cancer
por: Passaro, Antonio, et al.
Publicado: (2020)

Integrated Multiparametric High-Content Profiling of Endothelial Cells
por: Wiseman, Erika, et al.
Publicado: (2019)

Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface
por: Belluomini, L., et al.
Publicado: (2021)

Multiparametric statistics
por: Serdobolskii, Vadim Ivanovich
Publicado: (2007)

Evolution of prostate MRI: from multiparametric standard to less-is-better and different-is better strategies
por: Girometti, Rossano, et al.
Publicado: (2019)

Correlating Super-Resolution Microscopy and Transmission Electron Microscopy Reveals Multiparametric Heterogeneity in Nanoparticles
por: Andrian, Teodora, et al.
Publicado: (2021)

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
por: Incorvaia, Lorena, et al.
Publicado: (2020)

STING is a prognostic factor related to tumor necrosis, sarcomatoid dedifferentiation, and distant metastasis in clear cell renal cell carcinoma
por: Marletta, Stefano, et al.
Publicado: (2023)

Multiparametric ultrasound of prostate: role in prostate cancer diagnosis
por: Kaneko, Masatomo, et al.
Publicado: (2022)

A multiparametric method to assess the MIM deformable image registration algorithm
por: Calusi, Silvia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f55rinja1tihc2av0akpu11dmp